Trails Edge Capital Partners
Trails Edge Capital Partners reported 35 stocks worth $630M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are LBRX (7.8%), NRIX (6.1%) and IMCR (5.4%). Compared with Q1 2026, the fund opened new positions in TRAX, BMRN and INSM, added to LBRX, IMCR and FDMT, trimmed NRIX, MIRM and CYTK and sold out of PCVX, DFTX and RCUS.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  LBRX LB Pharmaceuticals Inc | $49.4M | 7.8% | 1.5M | +204K (+15%) | 3 of 3 | |
| 2 |  NRIX Nurix Therapeutics Inc | $38.2M | 6.1% | 1.6M | −170K (−10%) | 3 of 3 | |
| 3 |  IMCR Immunocore Hldgs PLC | $33.8M | 5.4% | 1.1M | +381K (+56%) | 3 of 3 | |
| 4 |  TRAX First Tracks Biotherapeutics | $30.5M | 4.8% | 1.5M | New position | 1 of 3 | |
| 5 |  FDMT 4D Molecular Therapeutics in | $29.6M | 4.7% | 2.2M | +925K (+71%) | 2 of 3 | |
| 6 |  BMRN Biomarin Pharmaceutical Inc | $29.3M | 4.7% | 512K | New position | 1 of 3 | |
| 7 |  DSGN Design Therapeutics Inc | $29M | 4.6% | 2M | +1.1M (+135%) | 2 of 3 | |
| 8 |  XENE Xenon Pharmaceuticals Inc | $26.6M | 4.2% | 440K | No change | 3 of 3 | |
| 9 |  MIRM Mirum Pharmaceuticals Inc | $26.1M | 4.2% | 223K | −110K (−33%) | 3 of 3 | |
| 10 |  INSM Insmed Inc | $24.6M | 3.9% | 230K | New position | 1 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Trails Edge Capital Partners 13F FAQ
What does Trails Edge Capital Partners own?
Trails Edge Capital Partners reported 35 stocks worth $630M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are LBRX (7.8%), NRIX (6.1%) and IMCR (5.4%). The table above lists every position in the filing (the top 10 without an account).
What did Trails Edge Capital Partners buy and sell in Q2 2026?
Compared with Q1 2026: 13 new positions, 10 added to, 7 trimmed and 4 sold out. New positions include TRAX, BMRN and INSM. It sold all of PCVX, DFTX and RCUS.
When will Trails Edge Capital Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Trails Edge Capital Partners's portfolio worth?
The Q2 2026 filing reports $630M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.